Clinical trials: Ranibizumab
Retinopathy of Prematurity
A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China
This is a 24-week, multicenter, open-label, single-arm, observational, post approval commitment study, which is designed to collect effectiveness, safety and other clinical information of intravitreal ranibizumab 0.2 mg for the…
- Trial name
- NCT05576792
- Testing
- Ranibizumab
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab
This is an open-label, Phase I/II study of intravitreally administered ranibizumab either 0.5-mg and/or 2.0-mg in subjects with clinical, angiographic, and ocular coherence tomography (OCT) evidence of diabetic retinopathy with…
- Trial name
- REEF (NCT01292798)
- Testing
- Ranibizumab
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- California Retina Consultants
Ophthalmopathy
Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)
To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to CRVO
- Trial name
- NCT04460001
- Testing
- Ranibizumab, triamcinolone acetate
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetic Macular Edema
Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema
Recent reports suggest that anti-VEGF agents (ranibizumab) may suppress the progression of retinal nonperfusion area. This protective effect would cause the increase of the oxygen consumption in the diabetic retina.
- Trial name
- NCT02329132
- Testing
- Ranibizumab
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Kagawa University
Choroidal Neovascularization
Use of Spectral OCT in Combination Therapy
This study will investigate the safety and efficacy of treatment of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) with a combination of ranibizumab (Lucentis) and verteporfin PDT (Visudyne), as…
- Trial name
- Spectral OCT (NCT01025063)
- Volunteers
- 15 people
- Sponsor
- Barnes Retina Institute
Retinopathy of Prematurity
Intravitreal Ranibizumab in Recurrent ROP
A retrospective study included reviewing of medical records of preterm babies who were admitted in neonatal intensive care unit (NICU) of Mansoura University children hospital (MUCH) or referred from nearby hospitals for ROP…
- Trial name
- NCT04539106
- Testing
- intravitreal injection of Ranibizumab
- Where
- Egypt
- Volunteers
- 115 people
- Sponsor
- Ameera Gamal Abdelhameed
Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic retinopathy.
- Trial name
- INIPE (NCT00993525)
- Testing
- Intravitreal injection of ranibizumab
- Volunteers
- 22 people
- Sponsor
- University of Sao Paulo
Age-Related Macular Degeneration
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis®…
- Trial name
- NCT03211234
- Testing
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Where
- 14 sites in United States, Philippines
- Volunteers
- 76 people
- Sponsor
- Santen Inc.
Diabetic Macular Edema
Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab
The aim of this study is to evaluate the one-year visual outcome and prognostic factors after intraocular injections of ranibizumab under pro re nata treatment regimen for the patients with diabetic macular edema (DME).
- Trial name
- IVRDME (NCT03973138)
- Testing
- Ranibizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Choroidal Melanoma
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that…
- Trial name
- NCT01251978
- Testing
- Ranibizumab 2 mg, 0.5 mg Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New England Retina Associates
Choroidal Neovascularization Secondary to Pathologic Myopia
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV).
- Trial name
- POYANG (NCT06176352)
- Testing
- Faricimab, Ranibizumab
- Where
- 63 sites in Australia, China and 9 more
- Volunteers
- 280 people
- Sponsor
- Hoffmann-La Roche
Wet Age-related Macular Degeneration
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
The purpose of this study is to compare the efficacy and safety of SCT510A versus Lucentis in the treatment of wet age-related macular degeneration.
- Trial name
- NCT05480293
- Testing
- Ranibizumab, SCT510A
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Sinocelltech Ltd.
Macular Degeneration
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and December 31…
- Trial name
- REVIEW (NCT01933152)
- Testing
- Ranibizumab
- Where
- Portugal
- Volunteers
- 137 people
- Sponsor
- Bayer
Age Related Macular Degeneration
The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot
Treatment of exudative age-related macular degeneration has been significantly improved by the advent of Lucentis™( which provides improved vision rather than simply stabilization) is common; however, monthly injections may be…
- Trial name
- MAP (NCT00605423)
- Testing
- Fluocinolone Acetonide/Medidur
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Macular Degeneration, Choroidal Neovascularization
Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging
Clinical trial investigating the role of hyperspectral imaging in the management of patients undergoing standard clinical treatment for naive neovascular choroidal membranes in age-related macular degeneration.
- Trial name
- NCT03105609
- Testing
- Hyperspectral imaging
- Where
- Australia
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Age-Related Macular Degeneration
Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing.
- Trial name
- NCT02291887
- Testing
- Ranibizumab, Aflibercept
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Associated Retinal Consultants, Michigan
Choroidal Neovascularization
Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)
The purpose of the study is to investigate the efficacy of a new drug called ranibizumab in the treatment of choroidal neovascularization in underlying angioid streaks due to Pseudoxanthoma elasticum.
- Trial name
- NCT00510965
- Testing
- Intravitreal injection ranibizumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital, Bonn
Diabetic Retinopathy, Postoperative Recurrent Vitreous Hemorrhage
A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy
Diabetic retinopathy (DR) is one of the main complications in diabetes, the proliferative diabetic retinopathy (PDR) is the most important one of the reasons leading to decreased vision, PDR is the stage of clinical intervention.
- Conditions
- Diabetic Retinopathy, Postoperative Recurrent Vitreous Hemorrhage, Pars Plana Vitrectomy, Ranibizumab
- Trial name
- NCT05248334
- Testing
- Ranibizumab Injection, PPV
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Eye Hospital
Retinopathy, Diabetic
Assessment of Color Vision in Diabetic Patients
Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema
- Trial name
- NCT03345667
- Testing
- lucentis
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Instituto de Olhos de Goiania
Von Hippel-Lindau Syndrome
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
This study will examine whether he drug ranibizumab can slow or stop the growth of angiomas (blood vessel tumors) in patients with Von Hippel-Lindau syndrome (VHL).
- Trial name
- NCT00089765
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)